330795-69-2Relevant articles and documents
2,3-Diarylthiophenes as selective EP1 receptor antagonists
Ducharme, Yves,Blouin, Marc,Carriere, Marie-Claude,Chateauneuf, Anne,Cote, Bernard,Denis, Danielle,Frenette, Richard,Greig, Gillian,Kargman, Stacia,Lamontagne, Sonia,Martins, Evelyn,Nantel, Francois,O'Neill, Gary,Sawyer, Nicole,Metters, Kathleen M.,Friesen, Richard W.
, p. 1155 - 1160 (2007/10/03)
The synthesis and the EP1 receptor binding affinity of 2,3-diarylthiophene derivatives are described. The evaluation of the structure-activity relationship (SAR) in this series led to the identification of compounds 4, 7, and 12a, which exhibit high affinity for the human EP 1 receptor and a selectivity greater than 100-fold against the EP2, EP3, EP4, DP, FP, and IP receptors and greater than 25-fold versus the TP receptor. These three antagonists present good pharmacokinetics in rats and significant differences in the way they are distributed in the brain.
Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
-
Example 4, (2008/06/13)
This invention encompasses the novel compounds of formula A, which are useful in the treatment of prostaglandin mediated diseases, or a pharmaceutically acceptable salt, hydrate or ester thereof. The invention also encompasses pharmaceutical compositions and methods for treatment of prostaglandin mediated diseases.
Method of treating or preventing urinary incontinence using prostanoid EP1 receptor antagonists
-
, (2008/06/13)
This invention encompasses a method of treating or preventing urinary incontinence in a mammalian patient comprising administering to the patient a compound of formula I: or a pharmaceutically acceptable salt, hydrate or ester thereof. The invention also encompasses certain pharmaceutical compositions and methods for treatment of prostaglandin mediated diseases comprising the use of compounds of formula I.
